全文获取类型
收费全文 | 221篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 10篇 |
妇产科学 | 3篇 |
基础医学 | 22篇 |
口腔科学 | 5篇 |
临床医学 | 17篇 |
内科学 | 27篇 |
皮肤病学 | 2篇 |
特种医学 | 25篇 |
外科学 | 16篇 |
综合类 | 6篇 |
预防医学 | 3篇 |
眼科学 | 1篇 |
药学 | 9篇 |
肿瘤学 | 99篇 |
出版年
2022年 | 1篇 |
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 6篇 |
2017年 | 3篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 7篇 |
2013年 | 13篇 |
2012年 | 5篇 |
2011年 | 5篇 |
2010年 | 10篇 |
2009年 | 10篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 6篇 |
2005年 | 10篇 |
2004年 | 15篇 |
2003年 | 5篇 |
2002年 | 12篇 |
2001年 | 15篇 |
2000年 | 5篇 |
1999年 | 6篇 |
1998年 | 5篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 3篇 |
1991年 | 9篇 |
1990年 | 8篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1973年 | 1篇 |
排序方式: 共有246条查询结果,搜索用时 515 毫秒
91.
Smart drugs: tyrosine kinase inhibitors in cancer therapy 总被引:17,自引:0,他引:17
Cancer therapy directed at specific, frequently occurring molecular alterations in signaling pathways of cancer cells has been validated through the clinical development and regulatory approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumors. While most novel, target-directed cancer drugs have pregenomic origins, one can anticipate a postgenomic wave of sophisticated "smart drugs" to fundamentally change the treatment of all cancers. With these prospects, interest in this new class of therapeutics extends from basic research scientists to practicing oncologists and their patients. An extension of the initial successes in molecular oncology will occur more quickly and successfully through an appreciation of lessons learned with the first group of agents in their progress through clinical development. 相似文献
92.
Edith A. Perez Michael F. Press Amylou C. Dueck Robert B. Jenkins Chungyeul Kim Beiyun Chen Ivonne Villalobos Soonmyung Paik Marc Buyse Anne E. Wiktor Reid Meyer Melanie Finnigan JoAnne Zujewski Mona Shing Howard M. Stern Wilma L. Lingle Monica M. Reinholz Dennis J. Slamon 《Breast cancer research and treatment》2013,138(1):99-108
A comprehensive, blinded, pathology evaluation of HER2 testing in HER2-positive/negative breast cancers was performed among three central laboratories. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) analyses were performed on 389 tumor blocks from three large adjuvant trials: N9831, BCIRG-006, and BCIRG-005. In 123 cases, multiple blocks were examined. HER2 status was defined according to FDA-approved guidelines and was independently re-assessed at each site. Discordant cases were adjudicated at an on-site, face-to-face meeting. Results across three independent pathologists were concordant by IHC in 351/381 (92 %) and FISH in 343/373 (92 %) blocks. Upon adjudication, consensus was reached on 16/30 and 18/30 of discordant IHC and FISH cases, respectively, resulting in overall concordance rates of 96 and 97 %. Among 155 HER2-negative blocks, HER2 status was confirmed in 153 (99 %). In the subset of 102 HER2-positive patients from N9831/BCIRG-006, primary blocks from discordant cases were selected, especially those with discordant test between local and central laboratories. HER2 status was confirmed in 73 (72 %) of these cases. Among 118 and 113 cases with IHC and FISH results and >1 block evaluable, block-to-block variability/heterogeneity in HER2 results was seen in 10 and 5 %, respectively. IHC?/FISH? was confirmed for 57/59 (97 %) primary blocks from N9831 (locally positive, but centrally negative); however, 5/22 (23 %) secondary blocks showed HER2 positivity. Among 53 N9831 patients with HER2-normal disease adjudicated as IHC?/FISH—(although locally positive), there was a non-statistically significant improvement in disease-free survival with concurrent trastuzumab compared to chemotherapy alone (adjusted hazard ratio 0.34; 95 % CI, 0.11–1.05; p = 0.06). There were similar agreements for IHC and FISH among pathologists (92 % each). Agreement was improved at adjudication (96 %). HER2 tumor heterogeneity appears to partially explain discordant results in cases initially tested as positive and subsequently called negative. 相似文献
93.
Andrea Wilcken Flavia Miiro-Nakayima Ramadhan NB Hizaamu Thomas Keil Dorothy Balaba-Byansi 《BMC public health》2010,10(1):209
Background
Medical male circumcision is now part of a comprehensive approach to HIV prevention. It has been shown that awareness of the protective effect of male circumcision leads to high acceptability towards the introduction of medical male circumcision services within countries. The objective of this survey was to identify factors determining awareness of male circumcision for HIV prevention. 相似文献94.
Yanyuan Wu Monica Alvarez Dennis J Slamon Phillip Koeffler Jaydutt V Vadgama 《BMC cancer》2010,10(1):32
Background
Epigenetic changes associated with promoter DNA methylation results in silencing of several tumor suppressor genes that lead to increased risk for tumor formation and for progression of the cancer. 相似文献95.
Fejzo MS Dering J Ginther C Anderson L Ramos L Walsh C Karlan B Slamon DJ 《Genes, chromosomes & cancer》2008,47(10):873-883
Approximately 25,000 ovarian cancers are diagnosed in the US annually, and 75% of cases are in the advanced stage when they are largely incurable. There is a critical need for improved early detection tools and development of novel treatments. Because chromosome band 20q13 is a commonly DNA amplified region in ovarian cancer and increase in 20q13 copy number may be an early event, we examined the DNA amplification and RNA expression pattern of 239 microarray probes mapping to this region with the goal of identifying gene(s) associated with ovarian cancer. Using Agilent expression microarray analysis and FISH to tumor tissue arrays, we narrowed the candidates to 19 genes that were consistently overexpressed in a subset of tumors amplified for both ZNF217 and TPD54, although, interestingly the candidates do not include these two amplified genes. Unsupervised clustering of 225 ovarian samples with respect to RNA expression of these 19 genes allowed identification of a 20q-amplified subset of 51 (23%) tumors and this subset was significantly correlated with poor outcome. Of the 19 candidate genes in this subset, ADRM1 overexpression was the most highly correlated with amplification, was amplified in a higher percentage of tumors than ZNF217 and TPD54, and was significantly upregulated with respect to stage, recurrence and metastasis. In addition, overexpression of ADRM1 correlates significantly with shorter time to recurrence and overall survival. Functional analysis is now warranted to determine whether ADRM1 is a target for early screening and/or therapy for ovarian cancer. 相似文献
96.
G E Konecny R Glas J Dering K Manivong J Qi R S Finn G R Yang K-L Hong C Ginther B Winterhoff G Gao J Brugge D J Slamon 《British journal of cancer》2009,101(10):1699-1708
Background:
Here, we explore the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and membrane-bound tyrosine kinases, including members of the Src kinase family, EphA2, and focal adhesion kinase for the treatment of ovarian cancer.Methods:
We examined the effects of dasatinib on proliferation, invasion, apoptosis, cell-cycle arrest, and kinase activity using a panel of 34 established human ovarian cancer cell lines. Molecular markers for response prediction were studied using gene expression profiling. Multiple drug effect/combination index (CI) isobologram analysis was used to study the interactions with chemotherapeutic drugs.Results:
Concentration-dependent anti-proliferative effects of dasatinib were seen in all ovarian cancer cell lines tested, but varied significantly between individual cell lines with up to a 3 log-fold difference in the IC50 values (IC50 range: 0.001–11.3 μmol l−1). Dasatinib significantly inhibited invasion, and induced cell apoptosis, but less cell-cycle arrest. At a wide range of clinically achievable drug concentrations, additive and synergistic interactions were observed for dasatinib plus carboplatin (mean CI values, range: 0.73–1.11) or paclitaxel (mean CI values, range: 0.76–1.05). In this study, 24 out of 34 (71%) representative ovarian cancer cell lines were highly sensitive to dasatinib, compared with only 8 out of 39 (21%) representative breast cancer cell lines previously reported. Cell lines with high expression of Yes, Lyn, Eph2A, caveolin-1 and 2, moesin, annexin-1, and uPA were particularly sensitive to dasatinib.Conclusions:
These data provide a clear biological rationale to test dasatinib as a single agent or in combination with chemotherapy in patients with ovarian cancer. 相似文献97.
Britten CD Kabbinavar F Hecht JR Bello CL Li J Baum C Slamon D 《Cancer chemotherapy and pharmacology》2008,61(3):515-524
Purpose Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently approved
for the treatment of imatinib-refractory GIST and advanced renal cell carcinoma at a dose of 50 mg daily for 4 weeks followed
by a 2-week off period (4/2 schedule). This trial was performed to investigate the safety, tolerability, and pharmacokinetics
of sunitinib 50 mg daily for 2 weeks followed by a 1-week off period (2/1 schedule).
Experimental design Twelve patients with advanced refractory malignancies were treated with sunitinib on the 2/1 schedule. Intensive safety monitoring
included serial measurements of left ventricular ejection fraction (LVEF). Extensive pharmacokinetic sampling was performed
on days 1 and 14 of course 1, and on day 14 of courses 2 and 3 to evaluate sunitinib and the SU12662 metabolite.
Results Twelve patients received a total of 50 courses with an average (±SD) off-drug period of 11.5 ± 5.7 days. Two patients experienced
DLT: one patient had asymptomatic grade 4 elevations in lipase and amylase, and another patient had an asymptomatic grade
2 decline in LVEF in course 1. In total, five patients demonstrated asymptomatic grade 2 declines in LVEF. Other principal
effects were similar to previous experience with sunitinib, including fatigue, myelosuppression, skin discoloration, and gastrointestinal
effects. Pharmacokinetic studies revealed no significant accumulation of sunitinib or SU12662. One patient with papillary
thyroid cancer developed a partial response, and was on study for 16 courses, followed by an additional 18 courses on a continuation
protocol.
Conclusions The 2/1 schedule of sunitinib 50 mg was tolerable, and no significant drug accumulation was demonstrated. The safety profile
on this schedule was consistent with the safety profile of sunitinib when administered on a 4-week on, 2-week off schedule.
Grant Support: National Cancer Institute/Avon Foundation Progress for Patients Award (Carolyn Britten), Stop Cancer Career
Development Award (Carolyn Britten). 相似文献
98.
A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases 总被引:2,自引:0,他引:2
To evaluate biologic characteristics of neuroblastoma, the authors examined the expression of Ha-ras gene (Ha-ras p21) in 103 primary tumors obtained at the time of diagnosis. Higher expression of the Ha-ras p21 in tumor cells showed a significant association with lower clinical stage of the tumor at diagnosis (chi-square = 35.418, degrees of freedom [df] = 9, P less than 0.001) and survival of the patients (chi-square = 37.111, df = 3, P less than 0.001). Thirty-six (84%) of 43 patients with decreased Ha-ras p21 expression died of aggressive disease. The Ha-ras DNA was examined in the 32 tumors by Southern blot analysis. Neither augmentation nor deletion of the Ha-ras DNA was observed. Amplification of the N-myc DNA was also examined in 43 cases in comparison with Ha-ras p21 expression. N-myc amplification was detected in 12 (55%) of 22 patients who died, and 19 (86%) of the 22 patients showed a low expression of the Ha-ras p21 in tumor cells. Eighteen (86%) of 21 survivors showed a high expression of the Ha-ras p21. The expression of Ha-ras p21 was thought to be a clinically important marker for prognosis in children with neuroblastoma. 相似文献
99.
Detection of intraventricular thrombi by computed tomography 总被引:2,自引:0,他引:2
Godwin JD; Herfkens RJ; Skioldebrand CG; Brundage BH; Schiller NB; Lipton MJ 《Radiology》1981,138(3):717
100.
Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens. 总被引:10,自引:3,他引:7
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
T Tanaka D J Slamon M J Cline 《Proceedings of the National Academy of Sciences of the United States of America》1985,82(10):3400-3404
To examine the efficiency of generating protein-reactive antipeptide antibodies, 35 peptides encoded by retroviral or cellular oncogenes were used to immunize rabbits. Thirty-two peptides elicited antipeptide antibodies, of which 56% reacted with their respective oncoproteins. The length of the immunizing peptide was an important factor in generating antibodies reactive with native protein. Similar peptides differing in a single or a few amino acids could elicite antisera of markedly different reactivities. 相似文献